Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials

Insider Monkey12-12

We recently compiled a list of the 10 AI News Investors Probably Missed. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other AI...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490382977?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/NBz1WxKNP795Qg2WU7hLvw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/198a1516872a8cd09220c99d73a2f530","is_english":true,"pubTime":"2024-12-12 21:55","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2490382977","market":"us","top_or_hot":-1,"title":"Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials","media":"Insider Monkey","content":"<div>\n<p>We recently compiled a list of the 10 AI News Investors Probably Missed. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other AI...</p>\n\n<a href=\"https://finance.yahoo.com/news/recursion-pharmaceuticals-rxrx-ai-driven-135521845.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRecursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-12 21:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/recursion-pharmaceuticals-rxrx-ai-driven-135521845.html><strong>Insider Monkey</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>We recently compiled a list of the 10 AI News Investors Probably Missed. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other AI...</p>\n\n<a href=\"https://finance.yahoo.com/news/recursion-pharmaceuticals-rxrx-ai-driven-135521845.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NVIW.SI","symbol_name":"NVDA 3xLongSG261006","start_time":0,"source_url":"https://finance.yahoo.com/news/recursion-pharmaceuticals-rxrx-ai-driven-135521845.html","article_id":"2490382977","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/NBz1WxKNP795Qg2WU7hLvw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/198a1516872a8cd09220c99d73a2f530"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490382977","pubTimestamp":1734011721,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"We recently compiled a list of the 10 AI News Investors Probably Missed.In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc.  stands against the other AI stocks.As artificial intelligence continues to reshape industries, experts are increasingly focusing on how its integration will impact investment strategies. The growth of AI presents a unique opportunity for investors to diversify their portfolios, not only by targeting leading tech companies but also by considering the broader ecosystem, including infrastructure and cybersecurity.In a CNBC interview, Jay Jacobs from BlackRock and ETF expert Dave Nadig discussed the future of ETFs in 2025, particularly focusing on the accelerating phase of AI infrastructure. Jacobs highlighted that AI adoption is still in its early stages, with significant investments being made by megacap tech companies in data centers, chips, and model training. He emphasized the importance of looking beyond just the tech giants, a","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NVIW.SI":"NVDA 3xLongSG261006",".IXIC":"NASDAQ Composite","QLD":"纳指两倍做多ETF","PSQ":"纳指反向ETF","BK4539":"次新股","TQQQ":"纳指三倍做多ETF","BK4548":"巴美列捷福持仓","USAW.SI":"AMZN 3xLongSG261006","USJW.SI":"ALPHAB 3xLongSG261006","SQQQ":"纳指三倍做空ETF","RXRX":"Recursion Pharmaceuticals, Inc.","QID":"纳指两倍做空ETF","TSYW.SI":"TESLA 3xLongSG261006","BK4139":"生物科技"},"translate_title":"Recursion Pharmaceuticals(RXRX)人工智能驱动的癌症治疗在早期试验中显示出希望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1,".IXIC":0.81,"MNQmain":0.6,"NQmain":0.6,"NVIW.SI":0.6,"PSQ":0.6,"QID":0.6,"QLD":0.6,"SQQQ":0.6,"TQQQ":0.6,"TSYW.SI":0.6,"USAW.SI":0.6,"USJW.SI":0.6},"content_text":"We recently compiled a list of the 10 AI News Investors Probably Missed. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other AI stocks.\nAs artificial intelligence continues to reshape industries, experts are increasingly focusing on how its integration will impact investment strategies. The growth of AI presents a unique opportunity for investors to diversify their portfolios, not only by targeting leading tech companies but also by considering the broader ecosystem, including infrastructure and cybersecurity.\nHow AI is Shaping the Next Wave of ETF Opportunities\nIn a CNBC interview, Jay Jacobs from BlackRock and ETF expert Dave Nadig discussed the future of ETFs in 2025, particularly focusing on the accelerating phase of AI infrastructure. Jacobs highlighted that AI adoption is still in its early stages, with significant investments being made by megacap tech companies in data centers, chips, and model training. He emphasized the importance of looking beyond just the tech giants, as other sectors like semiconductors, data centers, and software companies are poised to benefit from AI. Jacobs also pointed out that cybersecurity investments are becoming more crucial as the value of data grows.\nNadig added that AI's impact will also extend to infrastructure sectors, especially power, and emphasized the importance of retail companies integrating AI into consumer devices. Finally, both experts acknowledged the growing importance of physical infrastructure, such as electricity, data centers, and materials like copper, in supporting the rapid expansion of AI technologies.\nREAD ALSO: 11 Trending AI Stocks on Latest News and Ratings and 10 AI Stocks Taking Wall Street by Storm.\nAI as a Business Tool: Evolving Pricing Strategies\nOn December 10, Bloomberg reported that OpenAI CFO Sarah Friar discussed the potential for charging business users thousands of dollars per month for its AI software to better reflect its value. She explained that for users, such as lawyers or academics, AI tools could function like having a highly skilled assistant, making a higher subscription fee reasonable. Currently, OpenAI offers a $20-per-month plan for consumers and a $200 option for access to more powerful models.\nThe company also charges businesses on a per-user basis. In the future, Friar suggested the possibility of a value-based pricing model for AI products, based on the benefits companies gain, such as automating tasks and reducing the need for additional employees. This approach could help offset the high costs of developing AI systems.\nFor this article, we selected AI stocks by going through news articles, stock analysis, and press releases. We listed the stocks in ascending order of their hedge fund sentiment taken from Insider Monkey’s database of 900 hedge funds.\nWhy are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).\n A pharmacist in a hospital pharmacy stands next to a row of various drug containers. \nRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX)\nNumber of Hedge Fund Holders: 16\nRecursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a clinical-stage biotech company leveraging AI and technology to advance drug discovery. It also recently announced its LOWE Drug Discovery Software, a language model designed to streamline drug discovery by running experiments with AI on large datasets.\nRecursion (NASDAQ:RXRX) reported early data from its AI-designed CDK7 inhibitor, REC-617, in a Phase 1/2 trial for advanced solid tumors. Created through AI-led precision methods, REC-617 reached clinical testing within 12 months of candidate identification. It demonstrated promising pharmacokinetics and pharmacodynamics, with rapid absorption, controlled target engagement, and favorable safety. The study observed one partial response in a heavily pre-treated patient and stable disease in others. These findings highlight REC-617's potential for addressing resistance mechanisms in cancer therapy. Recursion plans further dose escalation and combination trials in 2025, emphasizing its AI-driven approach to drug development.\nOverall, RXRX ranks 8th on our list of AI news that investors probably missed. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RXRX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.\nREAD NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock.\nDisclosure: None. This article is originally published at Insider Monkey.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490382977"}